< Q Pharma, Inc. profile
Export
Valerion Therapeutics
Privately Held
Founded 2007
USA
Valerion Therapeutics, formerly 4s3 Bioscience, is developing therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system capable of enhanced intracellular delivery. Demonstrated pre-clinical in vivo data with the company’s two lead product candidates validates the potential of the 4s3 delivery platform for delivering muscle-protein fusions and treating multiple indications in the fields of muscular dystrophies and enzyme-deficiency disorders.
TRY OUR SIMILAR COMPANIES APP
- Find B2B Sales Prospects
- Research Competitive Landscapes
- Export Lists
Open Now
Medical Prognosis Institute
Privately Held
Founded 2004
Denmark
MPI is a pharmacodiagnostic company with proprietary pivotal technology (DNA microarray, qPCR based) which is universally applicable to any drug and any disease to determine Drug Response Prediction (DRP). Based on a small tumour sample or blood sample, MPI’s Drug Response Predictor™ it predicts which existing chemotherapeutic drug the tumour is most sensitive to. The tumour sample is analyzed on a DNA microarray and the gene expression profile is processed by MPI's proprietary patented software. The technology has been proven in several retrospective validations on a large number of patients, diseases, drugs, and biologics. Value Proposition: It has become apparent that most chemotherapeutic drugs on the market have varied efficacy with varying genetic profiles. This poses a challenge for both the treatment with and the development of these drugs. MPI's technology will allow developers of chemotherapeutic drugs to speed up drug development by providing a genetic profile of the most relevant patients for the drug to be tested. This will save significant amounts in development cost as well as increase the possibility of success.;Additionally oncologists will be able to use MPI's technology as a guide for selecting the most efficient chemotherapeutic drug or drug combinations for a specific patient.
Umea Institute of Design
n/a
Founded date unknown
Sweden
Umea Institute of Design offers masters programmes in Interaction Design, Transportation Design and Advanced Product Design.
Auris Medical
Publicly Traded
Founded 2003
Auris Medical is dedicated to the development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders. We at Auris Medical are dedicated to developing novel pharmaceutical therapies (we call them cochlear therapies) to protect hearing and to silence tinnitus. It is our ambition to provide therapies to prevent or treat important types of hearing loss or of tinnitus in a truly effective and safe way, based on sound science and careful clinical research.
PneumaCare
Privately Held
Founded 2009
United Kingdom
PneumaCare's lung function imaging devices are a revolutionary advancement in respiratory assessment that allow clinicians to rapidly identify pulmonary-related issues across a broader patient population, earlier in the patient-care lifecycle. Using PneumaCare's proprietary SLP technology, the PneumaScan™ and Thora-3DI™ capture functional images of the lungs by analysing chest wall movement, and translate this data into pulmonary function outputs. This is all done without any physical contact with the patient or the need to subject them to radiological or resonance treatments.
TRY OUR SIMILAR COMPANIES APP
- Find B2B Sales Prospects
- Research Competitive Landscapes
- Export Lists
Open Now
Sysmex Corporation
n/a
Founded date unknown
Along with its subsidiaries, Sysmex is involved in the development, manufacture and sale of laboratory testing reagents and laboratory equipment; the development and sale of computer systems for medical institutions, as well as the development and sale of software used for clinical examination information systems.
Upgrade for full access
Upgrade to a paid plan for: Full Access from$60.00 per monthYou have reached your free usage limit for today.
Upgrade Now
Your VentureRadar Business account is now active and
your account information has been sent to your email address.
You must have cookies enabled to create an account with VentureRadar
Return to home page
or
By continuing, you agree to VentureRadar's Terms of Service, Privacy Policy and Cookie Policy.